Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (20328)	10/4/2001 3:54:42 PM
From: Frederick Langford	Respond to of 208838

:) Fred

To: SusieQ1065 who wrote (20328)	10/4/2001 11:35:19 PM
From: Frederick Langford	Respond to of 208838

Biotechs 459.08 -16.13 -3.39% UBS Warburg lowered price targets on four genomics stocks while keeping its ratings unchanged: Celera Genomics (CRA: news, chart, profile), Myriad Genetics (MYGN: news, chart, profile), Human Genome Sciences (HGSI: news, chart, profile) and Millennium Pharmaceuticals (MLNM: news, chart, profile). The move, analyst Ricky Goldwasser said, reflects increased risk aversion in the market and a contraction in multiples of pharmaceutical and biotech companies. He added that the fundamentals for the mentioned companies remain intact. Goldwasser said Myriad remains his top pick in the genomics group due to its business model of building a therapeutic pipeline with a diagnostics business. Myriad fell 6.7 percent, Human Genome lost 5.0 percent, Millennium 4.5 percent and Celera 3.7 percent. Most of the stocks opened on a positive note before faltering in afternoon action. Fred